Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification

Genetics and Molecular Research

Volumn 14, Issue 2, 2015, Pages 4282-4290

  Wang, X Z ^a   Liu, Q ^a   Sun, J J ^a   Zuo, W S ^a   Hu, D W ^a   Ma, S G ^a   Mu, D B ^a   Yu, Z Y ^a  

^a UNIVERSITY OF JINAN   (China)

Author keywords

Breast neoplasm; EGFR; Immunohistochemistry; Molecular subtypes; P53

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST SURGERY; CANCER CLASSIFICATION; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; CLASSIFICATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928668603     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.April.28.10     Document Type: Article

References (26)

1. Bauer KR, Brown M, Cress RD, Parise CA, et al. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728.
2. Bennis S, Abbass F, Akasbi Y, Znati K, et al. (2012). Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res. Notes 5: 436-440.
3. Burness ML, Grushko TA and Olopade OI (2010). Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J. 16: 23-32.
4. Carey LA, Perou CM, Livasy CA, Dressler LG, et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
5. Curtis C, Shah SP, Chin SF, Turashvili G, et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
6. Dawood S, Broglio K, Esteva FJ, Yang W, et al. (2009). Survival among women with triple receptor-negative breast cancer and brain metastases. Ann. Oncol. 20: 621-627.
7. Dent R, Trudeau M, Pritchard KI, Hanna WM, et al. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13: 4429-4434.
8. El Fatemi H, Chahbouni S, Jayi S, Moumna K, et al. (2012). Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn. Pathol. 7: 170.
9. Goldhirsch A, Winer EP, Coates AS, Gelber RD, et al. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24: 2206-2223.
10. Grob TJ, Heilenkötter U, Geist S, Paluchowski P, et al. (2012). Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res. Treat. 134: 561-567.
11. Hammond ME, Hayes DF, Dowsett M, Allred DC, et al. (2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesteronereceptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134: e48-e72.
12. Howland NK, Driver TD, Sedark MP, Wen X, et al. (2013). Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer. J. Surg. Res. 185: 697-703.
13. Huang S, Benavente S, Armstrong EA, Li C, et al. (2011). p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res. 71: 7071-7079.
14. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, et al. (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J. Surg. Res. 143: 109-118.
15. Li J, Jia S, Zhang W, Zhang Y, et al. (2013). Survival analysis based on clinicopathological data from a single institution: chemotherapy intensity would be enhanced in patients with positive hormone receptors and positive HER2 in China who cannot afford the target therapy. ISRN Oncol. 2013: 606389.
16. Lin NU, Claus E, Sohl J, Razzak AR, et al. (2008). Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113: 2638-2645.
17. Masuda H, Zhang D, Bartholomeusz C, Doihara H, et al. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat. 136: 331-345.
18. Muñoz M, Fernández-Aceñero MJ, Martín S and Schneider J (2009). Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch. Gynecol. Obstet. 280: 43-48.
19. O’Brien KM, Cole SR, Tse CK, Perou CM, et al. (2010). Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin. Cancer Res. 16: 6100-6110.
20. Park S, Koo JS, Kim MS, Park HS, et al. (2012). Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21: 50-57.
21. Prat A, Cheang MC, Martin M, Parker JS, et al. (2013). Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 31: 203-209.
22. Raica M, Jung I, Cimpean AM, Suciu C, et al. (2009). From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change. Rom. J. Morphol. Embryol. 50: 5-13.
23. Shapira I, Lee A, Vora R and Budman DR (2013). P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. Crit. Rev. Oncol. Hematol. 88: 284-292.
24. Sjögren S, Inganäs M, Norberg T, Lindgren A, et al. (1996). The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88: 173-182.
25. Sparano JA, Goldestin LJ, Childs BH, Shak S, et al. (2009). Genotypic characterization of phenotypically defined triplenegative breast cancer. J. Clin. Oncol. 27 (Suppl): 15s.
26. Wiechmann L, Sampson M, Stempel M, Jacks LM, et al. (2009). Presenting features of breast cancer differ by molecular subtype. Ann. Surg. Oncol. 16: 2705-2710.